Literature DB >> 10228907

CA 125 in benign gynecological conditions.

H Meden1, A Fattahi-Meibodi.   

Abstract

The tumor marker CA 125 was initially thought to be specific for ovarian malignancies. Subsequently it was found to be raised in a variety of benign conditions, including pregnancy, pelvic inflammatory disease, tuberculosis and cirrhosis of the liver. With respect to gynecological tumors, CA 125 may be elevated in benign ovarian cysts, tubo-ovarian abscess, endometriosis, hyperstimulation syndrome, ectopic pregnancy and fibroids. These results demonstrate that CA 125 is a marker of non-specific peritoneal conditions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10228907     DOI: 10.1177/172460089801300411

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  27 in total

1.  Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Authors:  Richard G Moore; Michael Craig Miller; Elizabeth E Eklund; Karen H Lu; Robert C Bast; Geralyn Lambert-Messerlian
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

2.  Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.

Authors:  Richard G Moore; Michael Craig Miller; Margaret M Steinhoff; Steven J Skates; Karen H Lu; Geralyn Lambert-Messerlian; Robert C Bast
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

3.  Screening for ovarian cancer: imaging challenges and opportunities for improvement.

Authors:  K B Mathieu; D G Bedi; S L Thrower; A Qayyum; R C Bast
Journal:  Ultrasound Obstet Gynecol       Date:  2018-03       Impact factor: 7.299

4.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

5.  Abnormal CA-125 levels in menopausal women without ovarian cancer.

Authors:  Keith Y Terada; Jennifer Elia; Robert Kim; Michael Carney; Hyeong Jun Ahn
Journal:  Gynecol Oncol       Date:  2014-08-13       Impact factor: 5.482

Review 6.  Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?

Authors:  Julie L Hentze; Claus K Høgdall; Estrid V Høgdall
Journal:  Mol Clin Oncol       Date:  2019-01-11

7.  The role of CA125 in clinical practice.

Authors:  E L Moss; J Hollingworth; T M Reynolds
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

8.  Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands.

Authors:  Wei He; Sumith A Kularatne; Kimberly R Kalli; Franklyn G Prendergast; Robert J Amato; George G Klee; Lynn C Hartmann; Philip S Low
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

9.  Ovarian cancer pathogenesis: a model in evolution.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  J Oncol       Date:  2009-09-06       Impact factor: 4.375

Review 10.  Biomarkers in uterine leiomyoma.

Authors:  Gary Levy; Micah J Hill; Torie C Plowden; William H Catherino; Alicia Y Armstrong
Journal:  Fertil Steril       Date:  2012-11-29       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.